Clinical trial NCT03159078 - References

Critical Illness — Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

Citation(s)

•   Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E
  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008 Feb 15;46(4):567-70. doi
•   Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A
  Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowerin
•   Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R
  Colistin and rifampicin compared with colistin alone for t
•   Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A
  Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect.
•   Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of America
  Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adu
•   Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL
  Management of Adults Wit
•   Kassamali Z, Jain R, Danziger LH
  An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. Int J Infect Dis. 2015 Jan;30:125-32. doi: 10.1016/j.ijid.2014.10.014. Epub 2014 Nov 5. Review.
•   Kellum JA, Lameire N; KDIGO AKI Guideline Work Group
  Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 4;17(1):204. doi: 10.1186/cc11454. Review.
•   Landman D, Georgescu C, Martin DA, Quale J
  Polymyxins revisited. Clin Microbiol Rev. 2008 Jul;21(3):449-65. doi: 10.1128/CMR.00006-08. Review.
•   Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL
  Multidrug-resistant, extensively drug-resi
•   Maragakis LL, Perl TM
  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008 Apr 15;46(8):1254-63. doi: 10.1086/529198. Review.
•   Michel DJ, Knodel LC
  Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm. 1986 Jul;43(7):1709-14.
•   Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y
  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Ch
•   Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP
  Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aerugi
•   Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP
  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selectio
•   Seifert H
  The clinical importance of microbiological findings in the diagnosis and management of bloodstream infections. Clin Infect Dis. 2009 May 15;48 Suppl 4:S238-45. doi: 10.1086/598188.
•   Siddiqui NU, Qamar FN, Jurair H, Haque A
  Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infect Dis. 2014 Nov 28;14:626. doi: 10.1186/s1287
•   Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ
  Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004 Aug;54(2):566-9. Epub
•   Struelens MJ
  The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ. 1998 Sep 5;317(7159):652-4. Review.
•   Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M
  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenem
•   Zavascki AP, Bulitta JB, Landersdorfer CB
  Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1333-53. doi: 10.1586/14787210.2013.845523. Epub 2013 Nov 6. Review.

Polymyxin B Monotherapy Versus Polymyxin B-Carbapenem Combination Therapy in Critically Ill Patients With Multi-drug Resistant Gram-negative Infection: A Prospective, Parallel-Group, Double-Blind, Randomized Controlled Study

Details for clinical trial NCT03159078